Redcare Pharmacy stock falls sharply as analysts stick to Buy targets

Redcare Pharmacy N.V. (ISIN NL0012044747) stock traded lower again on Xetra, with the shares down 5.17 percent to 53.15 EUR on September 9, 2026, according to finanzen.ch.

Analysts reaffirm Buy ratings with high targets

Despite the recent share price weakness, coverage from major houses remains constructive. According to Finanztrends on September 10, 2026, Deutsche Bank reiterated its Buy recommendation for Redcare Pharmacy stock in early September and set a price target of 103.00 EUR.

The same article reports that Jefferies confirmed its Buy rating on September 3, 2026, with a target price of 97.00 EUR, underscoring that analysts still expect substantial upside from current levels, even after the correction seen in recent sessions.Finanztrends

Share price slide and distance to 52-week high

Redcare Pharmacy stock has been under pressure in recent days, with a marked move lower before the latest session. As Ad-hoc-news reported on September 10, 2026, the shares closed at 56.05 EUR on Xetra on September 8, 2026, losing 4.11 percent compared with the previous close of 58.45 EUR.

Market data from Finanzen100 on September 10, 2026, show that Redcare Pharmacy stock is trading clearly below its 52-week high of 90.10 EUR, while the 52-week low stands at 30.20 EUR.

At the same time, Finanzen100 lists a market capitalization of about 1,227,000,000 EUR as of September 10, 2026, giving investors a sense of the company’s size in the SDAX universe.Finanzen100

Current trading levels and volatility

Intraday volatility has recently increased. Ad-hoc-news describes that on September 8, 2026, the Xetra session saw Redcare Pharmacy stock trade between a day low of 55.55 EUR and a day high of 58.90 EUR, with around 81,821 shares changing hands and a reported cash volume of about 4,630,000 EUR.Ad-hoc-news

On September 10, 2026, the Xetra information page from comdirect shows an intraday quote of 54.00 EUR at 12:25 local time, with day volume of about 1,330,000 EUR and approximately 25,431 shares traded, and a prior close of 52.70 EUR, implying a daily gain of 2.47 percent at that moment.comdirect

For investors, this pattern of short-term swings around the low-to-mid-50s underscores both the sensitivity of the stock to wider market moves and the importance of the gap to the analyst consensus, which still points to significantly higher levels over a 12-month horizon.

Consensus expectations and upside potential

Beyond single-house views, aggregated data support the picture of a stock that analysts generally rate positively. The consensus overview on Redcare Pharmacy from MarketScreener shows a recommendation category of Buy and a medium price target of 87.50 EUR.

The same MarketScreener table indicates that the last closing price used in the consensus snapshot was 56.20 EUR, leaving a distance of 55.69 percent to the average target and even more to the highest price target of 116.00 EUR. This quantified gap between market price and analyst targets is a key element in many investors’ valuation arguments.MarketScreener

At the same time, the recent price drops show that consensus upside alone does not shield the shares from broader risk-off moves in European equities. A report from Interfax on September 10, 2026, notes that Redcare Pharmacy shares fell by about 6 percent in a session where several European names came under pressure as oil prices jumped, highlighting sector-wide and macro drivers.

Fundamental backdrop and strategic context

Recent articles emphasize that the fundamental story is still closely linked to digital health trends. Finanztrends points out that progress in national health infrastructure, such as the creation of a basis for a Health ID by the German digital health agency gematik, is seen as supportive for Redcare Pharmacy’s long-term positioning in online pharmacies and digital care.Finanztrends

Although no new quarterly or half-year figures were released in the last few days, the analyst optimism and the structural digitalization drivers described in that coverage indicate that the investment case continues to rest on revenue growth potential as electronic prescriptions and health IDs gain traction. For investors, the combination of a marked price drawdown and intact strategic backdrop is central to the current debate about the stock.

Redcare Pharmacy stock price as of September 10, 2026

As of September 10, 2026, around midday, Redcare Pharmacy stock on its primary listing Xetra was quoted at 54.00 EUR, with the prior close at 52.70 EUR, a day change of 2.47 percent, and intraday trading between 51.30 EUR and 54.00 EUR, based on comdirect’s Xetra data at 12:25 local time. This places the shares significantly below the 52-week high of 90.10 EUR recorded in the Finanzen100 overview, while the 52-week low stands at 30.20 EUR, underlining the scope of the recent correction.

More news and analyses on Redcare Pharmacy stock